Head of Sandoz UK becomes BGMA chair
pharmafile | May 31, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sandoz, appointment, bgma, pharma
Tim de Gavre has been announced as the new chair for the British Generic Manufacturers Association (BGMA), a position he will now retain for the next two years.
De Gavre will join the leadership team of the association after having worked as the chair for British Biosimilar Association since its foundation in 2016.
The BGMA is a membership organisation representing UK based manufacturers and suppliers of generic medicine, with a backing that represents 90% of the total UK generics market.
Its aim is to promote the use of generic medicines in the UK, a country that has a higher-than-average use of generics.
Tim de Gavre, said: “It is a huge honour to be asked to be the association’s chair for the next two years. Generics and biosimilars save the NHS over £13 billion on an annual basis, which not only releases NHS money for investment in new medicines but also increases accessibility as more patients can be treated for less.”
He continued, “During my tenure as chair of the BGMA, I want to find ways to support the NHS to better utilise generic medicines, while creating a more reliable and sustainable environment for manufacturers. The next two years promise to be critical with the introduction of the Falsified Medicines Directive and BREXIT both taking place in early 2019. I look forward to working with government, the NHS and other members of the BGMA to ensure the association’s voice remains strong and that generics and biosimilars are recognised for the value that they bring to the UK.”
Alongside his role as chair of the BGMA, he will continue in his role as leader of the Sandoz UK team, a role he assumed this time last year. He has worked at Sandoz since 2010 across numerous positions, including within both biosimilars and generics.
Prior to this, he had worked as a consultant at McKinsey and as a for healthcare venture capital firm, Frazier Healthcare Ventures.
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Sandoz opens biosimilar development centre in Slovenia
Sandoz has opened a new biosimilar development centre in Ljubljana, Slovenia, as part of efforts …
